Chemotherapy Effect, Circulating Tumor DNA, HER2-positive Breast Cancer
Conditions
Brief summary
Locally advanced breast cancer (LABC) is defined as breast cancer (BC) larger than 5 centimeters or with lymph node metastasis. Usually, LABC is treated with neoadjuvant chemotherapy (NAC) followed by curative surgery to reduce tumor size and eliminate micrometastasis. Response to NAC helps predict BC prognosis. Pathologic complete response (pCR), defined as no residual tumor cells after NAC, represents prolonged survival without BC recurrence and residual cancer burden score, based on residual tumor volume, and can more accurately predict BC outcomes. Especially, Human epidermal growth factor receptoor type 2(HER2)-positive breast cancer, having aggressive biologic characteristics, was mostly treated by NAC because of recent advance of highly effective targeted agents (pertuzumab and trastuzumab). However, still 30-40% of HER2-positive breast cancer did not response to NAC and underwent disease recurrence. Recently, genetic studies to find biomarker of BC prognosis have been widely performed. Circulating tumor DNA (ctDNA), which is circulating free DNA in the blood that originates from cancers, can be detected by recently-developed technologies. CtDNA could facilitate early disease detection, diagnosis and detection of disease recurrence. CtDNA also provides a genomic profile of BC and predicts drug response. In BC, ctDNA correlates with tumor burden and provides early detection of treatment response and tumor genetic alterations. In this study, the investigator aimed to identify the correlations in genomic profile between tumors and ctDNA during NAC(docetaxel /carboplatin /trastuzumab and pertuzumab) in HER2 positive breast cancer.
Interventions
DIAGNOSTIC_TESTLiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)
LiquidSCAN : detection of circulating DNA CancerSCAN : detection of somatic mutation using tumor tissue
Sponsors
Samsung Medical Center
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HER2+ Breast cancer * Stage IIA - IIIC * Plan to receive neoadjuvant chemotherapy with docetaxel, carboplatin, herceptin, perjeta * Sign to informed consent
Exclusion criteria
* Double primary cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pathologic complete response | Pathologic Clinical response is performed after end of cycle 6 (each cycle is 21 days) | pCR of neoadjuvant(TCHP) chemotherapy with the patients with HER2 positive BC. |
Countries
South Korea
Outcome results
None listed